Bounou Salim

Bounou Salim

+212(0)538 990 3213

  • Postdoctorat, Vrije University of Amsterdam, Nederlands (2003-2003) PostDoctorat
  • Université Laval (Québec-Canada) 1994-1996 Philosophiae Doctor (Ph.D.)
  • Université Laval (Québec-Canada) 1998-2002 Master of Science (Ph.D.)
  • Université Mohamed V (Rabat-Maroc) 1987-1991 Bachelor (B.SC)

Formation additionnelle 

  • Technology development and commercialization. Réseau inter-universitaire pour la Valorisation des produits de la Recherche, Interval, Montréal, Canada (2005-2006)
  • Expertise in management of innovation . Alliance for Commercialization of Canadian Technologies (ACCT) (2006, 2007, 2008)
  • Patentability opinions, validity and counterfeiting opinions, patent applications, international patent purchases, negotiation of licensing agreements, and mergers / acquisitions.
  • Intellectual Property Expertise Offices training (2006, 2007, 2008, 2009): Robic, Norton Rose, BCF, Smart & Biggar, Fasken Martineau

  • Virologie
  • Système immunitaire
  • Migration cellulaire - cell-based drug delivery system
  • Biologie moléculaire et biotechnologie
  • Enseignement des sciences
  • Propriété intellectuelle et management de l’innovation

  • 2019 to today Professor and Dean of Pole of Health -Université Euro-Méditerranéenne de Fès (UEMF)-
  • 2013 to 2018 Professor, Chargé de mission auprès du Président-Université Euro-Méditerranéenne de Fès (UEMF)-
  • 2011-2013 Projects Director –Technology Transfer Manager-Gestion Socpra Sec. & Université de Sherbrooke TransferTech-Sherbrooke, CANADA
  • 2009-2011 Director of MAScIR Valor-Fondation MAScIR-Moroccan Foundation for Advanced Sciences, Innovation and Research, Rabat, Morocco
  • 2007-2009 Projects Director –Technology Transfer Manager-Gestion Socpra Sec. & Université de Sherbrooke-Sherbrooke, CANADA
  • 2003-2009 Professor-Researcher-Université de Sherbrooke-Sherbrooke, CANADA
  • 1995, 1996, 1997 Assistant d’enseignement-Université Laval-Québec, CANADA
  1. Sanaa Zebakh, Jaouad Anissi, Salim BOUNOU. Indicators from patent data: The contribution of Moroccan higher education and research institutions to innovation in the agricultural field. Submitted to Scientometrics. June 2020. IF: 2,7
  2. Côté SC, Pasvanis S, Bounou S, Dumais N. CCR7-specific migration to CCL19 and CCL21 is induced by PGE(2) stimulation in human monocytes: Involvement of EP(2)/EP(4) receptors activation. Mol Immunol. 2009 Aug;46(13):2682-93. Epub 2009 Jul 9.  IF: 3,1
  3. Boisvert M, Côté S, Vargas A, Pasvanis S, Bounou S, Barbeau B, Dumais N. PGJ2 antagonizes NF-kappaB-induced HIV-1 LTR activation in colonic epithelial cells. Virology. 2008 Oct 10;380(1):1-11. Epub 2008 Aug 27. IF: 2,59
  4. Michel Ouellet,* Simon Mercier,* Isabelle Pelletier,† Salim Bounou,* Jocelyn Roy,* Jun Hirabayashi,‡ Sachiko Sato,2† and Michel J. Tremblay2*2005. Galectin-1 acts as a soluble host factor that promotes HIV-1 infectivity through stabilization of virus attachment to host cells. J.Immunol. 2005 Apr 1;174(7):4120-6.  IF: 6,8
  5. Bounou, S., Giguère, J.-F., Cantin, R., Gilbert, C., Imbeault, M., Martin G., Tremblay, M.J, 2004. The importance of virus-bound host ICAM-1 in HIV-1 transfer depends on the cellular context. FASEB J. 2004 Aug 1, 2004; 18 (11).  IF: 6,88
  6. Salim Bounou*, Jean-François Giguère*, Jean-Sébastien Paquette and Michel J. Tremblay 2004. Incorporation of host CD80 (B7.1) and CD86 (B7.2) glycoproteins into HIV-1 increases viral infectivity in primary human mononuclear cells. J Virol. 2004 Jun;78(12):6222-32.  IF: 5,54         *Co-first author
  7. Dumais N, Pare ME, Mercier S, Bounou S, Marriot SJ, Barbeau B, Tremblay MJ., 2003. T-cell receptor/CD28 engagement when combined with prostaglandin E2 treatment lead to potent activation of human T-cell leukemia virus type transcription. J Virol. 2003 Oct 15;77(20):11170-11179. IF: 5,54
  8. Jean-François Giguère, Jean-Sébastien Paquette, Salim Bounou, and Michel J. Tremblay, 2002. New insights into the functionality of a virion-anchored host cell membrane protein: CD28 versus human immunodeficiency virus type 1. J. Immunol. 2002 Sep 1;169(5):2762-71. IF: 7,01
  9. Bounou, Jacques E. Leclerc, and Michel. J. Tremblay, 2002. The presence of host ICAM-1 in laboratory and clinical strains of HIV-1 increases virus infectivity and CD4+ T-cell depletion in human lymphoid tissue, a major site of replication in vivoJ. Virol. 2002 Feb 1;76(3):1004-1014. IF: 5,54
  10. Nancy Dumais, Salim Bounou, Martin Olivier and Michel J. Tremblay, 2002. The CCAAT/Enhancer-binding protein is required for mediating cAMP responsiveness on HIV-1 LTR-driven gene activity in T cells mediated by prostaglandin E2. J. Immunol. 2002 Jan 1;168(1):274-82. IF: 7,01
  11. Salim Bounou, Dumais Nancy, Tremblay Michel J, 2001Attachment of HIV-1 particles bearing host-encoded B7-2 proteins leads to NF-B- and NFAT-dependent activation of HIV-1 LTR transcription. J Biol Chem. 2001 Mar 2;276(9):6359-69. IF: 6,69
  12. Salim Bounou, Suha H. Jabaji-Hare, Richard Hogue and Pierre M. Charest, 1999. Polymerase chain reaction-based assay for specific detection of Rhizoctonia solani AG-3 isolates.  Mycological Research Vol 103, part 1, p.1-8. IF: 1,52



  1. Benmoussa Othmane, Slighoua Mounia, Gmira Maha, and Bounou, Salim. The SARS-CoV-2 Pandemic Management: The Case of Morocco. Euro-Mediterranean Network for Economic Studies. EMNES Working Paper No33/ June, 2020. 
  2. Benmoussa Othmane, Slighoua Mounia, Bachiri Housseine, Bounou Salim. Entrepreneurship and Traditional Know-How: The Case of Moroccan Rural Women. Benmoussa Othmane, Slighoua Mounia, Bachiri Housseine, Bounou Salim. Euro-Mediterranean Network for Economic Studies. EMNES WORKING PAPER / june, 2019 under edition.


Conferences and Seminars

1. Innovation et Valorisation de la recherche-Éléments juridiques.  MedBiotech Conférences. Faculté de médecine et de pharmacie de Rabat, Maroc, 19 décembre 2019.

2. Les différents types de contrats recherche publiqueentreprise et transferts, Ententes de licence- Les bases de la négociation. CNRST, Rabat, Maroc. 31 octobre et 1 novembre 2019.

3. Les éléments juridiques de la valorisation de la recherche. CNRST, Rabat, Maroc. 23 juillet 2016

4. First analysis of potential innovation and assessment of needs to improve valorization of research results. ARIMNET. 11 juin 2014 - Campus de la Gaillarde INRA-SupAgro, Montpellier, France.

5. Knowledge enhancement and technology transfer. 30 juin 2012, Compétences Médicales Marocaines du Monde (C3M) &Faculté de médecine de Casablanca, Maroc.

6. Valorisation et essaimage technologique : Point de vue de l’Université de Sherbrooke. Journée sur la valorisation des résultats de la recherche. Université Mohammed V- Souissi, 7 mai 2009, Rabat, Maroc.

7. Maintain competitive advantage through innovation. 23 octobre 2008, IBM-Bromont, Canada.

8. La gestion de la propriété intellectuelle et commercialisation des produits de la recherche à l’Université de Sherbrooke. Faculté d’Administration, Université de Sherbrooke, 20 mai 2008, Sherbrooke, Canada et Touraine Board of Trade - Chamber of Commerce Touraine.

9. New therapeutic strategy to counter bacterial and viral infections. A Biopharmaceutical Partnership Symposium, special meeting of industry leaders, October 3, 2007, Château Frontenac, Québec, Canada.

10.  Plasminic biosensor based on semiconductor. Workshop on innovating industrial processes applied to new materials Hotel DELTA, October 2nd , 2007,  Sherbrooke, Canada.

11.  An device for rapid detection of infectious agents. The Canadian Institute for Photonic Innovations, a Network of Centers of Excellence. October 20th, 2006, Montréal, Canada.

12.  Host Proteines incorporated in HIV envelope : Pathogenesis. Health Products and Food Branch, Bureau of Microbial Hazards, Health Canada, Sir Frederick G. Banting Research Centre, Tunney's Pasture, P. L. 2204A2, February 15, 2005, Ottawa, Ontario. Canada.

13.  Les molécules de l’hôte incorporées dans l’enveloppe du HIV-1 : Pathogenèse de l’infection. Centre de recherche en inflammation, Centre Hospitalier de l’Université de Sherbrooke (CHUS), January 13, 2003, Sherbrooke, Canada.

14.  Les molécules de l’hôte incorporées dans l’enveloppe du HIV-1 : Incorporation de la molécule ICAM-1-Pathogenèse de l’infection. Centre Hospitalier Universitaire de Montréal (CHUM), Université de Montréal, July 26, 2002, Montréal, Canada.

15.  Host Proteines incorporated in HIV envelope : Pathogenesis. Center for Biomedical Research, Population Council, Rockefeller University, April 30, 2002, New York, USA.

16.  HIV infection : host proteins incorporated in the envelope oh HIV-1. Institut National de Recherche Scientifique en Santé (INRS-Santé), Jun 22, 2001, Pointe-Claire, Québec, Canada.

17.  Rôle des molécules de l’hôte dans la pathogénèse de l’infection HIV. Faculté des Sciences Dhar Mehraz, Université Sidi Mohammed Ben Abdallah, November 21, 2000, FES, MAROC.

  • Microbiologie
  • Immunologie
  • Biologie cellulaire
  • Biologie moléculaire
  • Biotechnologie médicale
  • Management de l’innovation, Entreprenariat
Fellowship Canadian Institutes of Health Research (CIHR) TOP 25 among 570 candidates 2003 - 2006
Post-Doctoral-Fellow Rockefeller University, New York, USA 2002-2003
Ph.D. scholarship Canadian Institutes of Health Research (CIHR) 2001-2004
Ph.D. scholarship FCAR-FRSQ, Québec, Canada 1999-2001
Full Scholarships (8-fold) International conferences in medical science between 2001-2003